This website is intended for UK residents only


Home / References
  1. NHS: Accessed May 2024
  2. Laxido® Orange. Summary of Product Characteristics. November 2021.
  3. Laxido® Paediatric Plain. Summary of Product Characteristics. November 2021.
  4. NHS. Accessed May 2024
  5. Dm+d Online. Accessed May 2024
  6. Gray JR. What is chronic constipation? Definition and diagnosis. Can J Gastroenterol. 2011 Oct; 25(Suppl B): 7B–10B Accessed May 2024
  7. Forootan M, Bagheri N, Darvishi M. Chronic constipation: A review of literature. Medicine (Baltimore). 2018 May;97(20):e10631. doi: 10.1097/MD.0000000000010631. PMID: 29768326; PMCID: PMC5976340.
  8. NHS: Accessed May 2024
  9. Accessed May 2024
  10. Data on file. 01
  11. NICE Accessed May 2024
  12. MOVICOL® 13.8g sachet, powder for oral solution. Summary of Product Characteristics. Jan 2024
  13. MOVICOL® 6.9g Paediatric Plain sachet, powder for oral solution. Summary of Product Characteristics. Jan 2024
  14. Heaton KW, et al. How bad are the symptoms and bowel dysfunction of patients with irritable bowel syndrome? A prospective controlled study with emphasis on stool form. Gut 1991; 32: 73–79.
  15. Allen S. How to deal with constipation. The Pharmaceutical Journal. 2007; 279: 23-26.

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects, you can help provide more information on the safety of this medicine.

The information provided on this site is for the use of Laxido Orange in those aged 12 years and above. Please speak to your doctor, nurse or pharmacist about the treatment of constipation in children under 12 years of age.

You are about to leave this Laxido® website to go to an external website.

Galen Ltd does not take any responsibility for content hosted on external websites.

Click to proceed